A simple blood protein measured during routine pregnancy testing may help doctors spot a hidden metabolic culprit behind recurrent miscarriage, according to new research from China. Scientists at Dongguan Maternal and Child Health Care Hospital report that low circulating levels of adiponectin, an insulin-sensitizing hormone secreted by fat tissue, are strongly associated with insulin resistance in women suffering from unexplained recurrent spontaneous abortion, a devastating condition in which pregnancies fail repeatedly despite exhaustive investigation. The findings, published in BMC Endocrine Disorders, suggest that a single, stable, easily measured protein could one day help clinicians decide which of these patients should undergo full metabolic workups.
Unexplained recurrent spontaneous abortion, typically defined as two or more consecutive pregnancy losses with no identifiable cause, affects an estimated one to five percent of reproductive-age women. For many, no chromosomal, anatomical, hormonal or thrombotic explanation is ever found, leaving both patients and physicians without a clear therapeutic target. In recent years, however, growing evidence has implicated insulin resistance as a modifiable contributor. Insulin resistance, in which the body’s tissues respond poorly to the hormone insulin, is common in conditions such as polycystic ovary syndrome and type 2 diabetes, and it is thought to disturb the delicate metabolic environment required for successful embryo implantation and early placental development.
The standard screening tool for insulin resistance in clinical practice is the homeostasis model assessment of insulin resistance, or HOMA-IR, an index calculated from fasting blood glucose and fasting insulin concentrations. Although convenient in principle, HOMA-IR has practical drawbacks in busy reproductive clinics. Because the calculation requires both measurements to be taken after an overnight fast, patients must return for a dedicated morning blood draw, adding inconvenience, cost and delay. Moreover, HOMA-IR is itself only a surrogate; the true gold standard for quantifying insulin sensitivity, the hyperinsulinaemic–euglycaemic clamp, is far too labor-intensive for routine care. The research team, led by Lujing Chen, Feiyan Li and Yacong Cao with senior authors Yihong Guo, Hui Chen and Ping Zhou, set out to determine whether serum adiponectin could serve as an adjunctive flag for insulin resistance in this specific and vulnerable patient population.
Adiponectin is an attractive candidate for several reasons. Unlike many circulating biomarkers, it is almost exclusively produced by adipose tissue, and it acts directly to enhance insulin sensitivity in liver and skeletal muscle through activation of AMP-activated protein kinase and related signaling pathways. Critically for screening purposes, adiponectin concentrations exhibit low biological variability and minimal post-prandial fluctuation, meaning they remain relatively stable throughout the day and are less affected by recent meals than glucose or insulin measurements. Levels tend to fall as insulin resistance worsens, providing an inverse window into metabolic health.
The study was a single-centre retrospective observational analysis of women managed for unexplained recurrent spontaneous abortion at the tertiary maternal and child health hospital in Dongguan, in southern China’s Guangdong province. All 404 participants were of Chinese Han ethnicity; 346 were non-pregnant and 58 were in early pregnancy. Serum total adiponectin was quantified using latex-enhanced immunoturbidimetry on a Hitachi 7180 automated analyser, a robust platform with an intra-assay coefficient of variation of 3.2 percent and an inter-assay coefficient of variation of 5.1 percent. Insulin resistance was defined as a HOMA-IR value of 2.41 or greater, and adiponectin was measured from the fasting blood sample obtained during the participants’ oral glucose tolerance testing. The researchers deliberately designated the non-pregnant subgroup of 346 women as the primary analysis population, since pregnancy itself alters both insulin sensitivity and adipokine profiles, with the full cohort analysed secondarily.
The results were strikingly consistent. Half of the cohort, 203 of the 404 women, met the criterion for insulin resistance. Serum adiponectin was significantly lower in the insulin-resistant group than in the insulin-sensitive group, with a median of 6.40 micrograms per milliliter in the resistant group compared with 8.50 micrograms per milliliter in the non-resistant group, a difference that was highly statistically significant. Across the entire cohort, adiponectin showed a clear inverse correlation with HOMA-IR, with a Spearman correlation coefficient of minus 0.455, and adiponectin levels declined in a graded fashion across ascending quartiles of HOMA-IR, confirming a dose–response relationship between worsening insulin resistance and falling adiponectin.
Beyond correlation, the team asked whether adiponectin could actually discriminate between insulin-resistant and insulin-sensitive women, and whether it added information beyond what age and body mass index already provide. In the primary non-pregnant analysis, adiponectin alone yielded an area under the receiver operating characteristic curve of 0.733, indicating moderate discriminative ability, and a similar value of 0.711 in the full cohort. Adding adiponectin to a statistical model containing age and body mass index increased the area under the curve from 0.759 to 0.788, an improvement that reached statistical significance on formal DeLong testing. The optimal diagnostic threshold, identified by maximizing the Youden index, was an adiponectin concentration of 6.60 micrograms per milliliter or lower. At this cut-off, the test achieved a sensitivity of 58.3 percent but a specificity of 78.7 percent, together with a positive predictive value of 72.1 percent, a negative predictive value of 66.7 percent and a positive likelihood ratio of 2.73. In other words, a low adiponectin result makes insulin resistance substantially more likely and is reliable when it points toward the diagnosis, even though it will miss a proportion of affected women.
The robustness of the association held up under scrutiny. When the researchers repeated their analyses using alternative HOMA-IR thresholds of 2.0, 2.5 and 3.0, the area under the curve for adiponectin remained within a narrow and consistent range of 0.697 to 0.724, indicating that the marker’s performance does not depend on the precise definition of insulin resistance chosen. Multivariable logistic regression, adjusting for age, body mass index and pregnancy status, confirmed that adiponectin is independently associated with insulin resistance: each 1 microgram per milliliter decrease in adiponectin concentration was associated with a 17 percent increase in the odds of insulin resistance, with an adjusted odds ratio of 1.17.
The clinical logic of the proposed approach is one of triage rather than replacement. Because adiponectin’s specificity outweighs its sensitivity, a low result could reasonably raise suspicion and prompt confirmatory fasting glucose and insulin testing, while a normal result would not by itself exclude insulin resistance. For women already undergoing oral glucose tolerance testing as part of recurrent pregnancy loss workups, the additional adiponectin measurement requires no extra blood draw and no extra fasting visit, since it can be run on the same fasting sample. This practicality is precisely what makes the marker appealing in resource-conscious reproductive clinics, where streamlining the diagnostic pathway for insulin resistance could accelerate the identification of a treatable contributor to pregnancy loss.
The authors are careful to frame their conclusions within the limits of the study design. This was a retrospective, single-centre investigation conducted in a homogeneous Chinese Han population, and its cross-sectional nature means it demonstrates association rather than causation. Importantly, the study does not show that adiponectin predicts pregnancy prognosis, nor that management guided by adiponectin levels improves reproductive outcomes. The researchers emphasize that prospective validation in independent, more diverse cohorts is required before adiponectin can be recommended as a clinical triage marker in routine care. If such validation succeeds, however, the implications could extend beyond recurrent miscarriage, since adiponectin’s stability and assay accessibility make it a candidate for metabolic screening in other reproductive contexts, including polycystic ovary syndrome and pregestational diabetes care.
For the millions of women worldwide who endure the heartbreak of unexplained pregnancy loss, the prospect of uncovering a modifiable metabolic driver is deeply significant. Insulin resistance, unlike genetic or immunological causes, can often be addressed through lifestyle intervention and established medications, potentially converting a hopeless diagnosis into a manageable one. This study adds a plausible, low-cost tool to the diagnostic toolkit, suggesting that a hormone long studied in obesity and diabetes research may deserve a place in the reproductive medicine clinic. The road from retrospective biomarker analysis to validated clinical practice is long, but the direction of travel, from adipose tissue biology to better care for women who have suffered repeated pregnancy loss, is now clearly marked.
Subject of Research: Serum adiponectin as an adjunctive marker for HOMA-IR-defined insulin resistance in women with unexplained recurrent spontaneous abortion
Subject of Research: Medicine
Article Title: Discriminative value of serum adiponectin as a potential adjunctive marker for HOMA-IR-defined insulin resistance in women with unexplained recurrent spontaneous abortion
Article References: Chen, L., Li, F., Cao, Y., Li, Y., Li, Z., Chen, C., Su, R., Guo, Y., Chen, H., & Zhou, P. (2026). Discriminative value of serum adiponectin as a potential adjunctive marker for HOMA-IR-defined insulin resistance in women with unexplained recurrent spontaneous abortion. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02512-7
Image Credits: AI Generated
DOI: 10.1186/s12902-026-02512-7
Keywords: Adiponectin, Insulin resistance, Recurrent spontaneous abortion, HOMA-IR, Adjunctive marker, Reproductive medicine, Biomarker, Pregnancy loss
Cite Scienmag News
APA MLA Chicago
Ophelia Keating. (September 9, 2026). Serum adiponectin may help identify insulin resistance in recurrent miscarriage. Scienmag. https://scienmag.com/serum-adiponectin-may-help-identify-insulin-resistance-in-recurrent-miscarriage/
Ophelia Keating. “Serum adiponectin may help identify insulin resistance in recurrent miscarriage.” Scienmag, 9 September 2026, https://scienmag.com/serum-adiponectin-may-help-identify-insulin-resistance-in-recurrent-miscarriage/. Accessed 9 September 2026.
Ophelia Keating. “Serum adiponectin may help identify insulin resistance in recurrent miscarriage.” Scienmag. September 9, 2026. https://scienmag.com/serum-adiponectin-may-help-identify-insulin-resistance-in-recurrent-miscarriage/
Copy citation Download RIS
Tags: adiponectin hormonefat tissue hormoneshormonal biomarkers in obstetricsinsulin resistanceinsulin resistance detectioninsulin-sensitizing hormonesmetabolic biomarkers in pregnancymetabolic causes of pregnancy lossmetabolic disorder detectionmetabolic workup in miscarriagepregnancy complication biomarkerspregnancy complication markerspregnancy loss diagnosispregnancy outcome predictionrecurrent miscarriagereproductive endocrinologyReproductive Healthrole of adiponectin in pregnancySerum adiponectinunexplained pregnancy lossunexplained spontaneous abortion
